Category: DRUG TRIAL
Novel EGFR Lung Cancer Drug, Dacomitinib Gains FDA Priority Review
The understanding of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been evolved over years. TKIs are found ...
New Potential Immuno-Oncology Drug for Blood Cancer Received Orphan Drug Status
Chinese biotech, Maxinovel Pharma’s immuno-oncology drug candidate- MAX-40279 received Orphan Drug designation from the US FDA for the treatment of ...
Ovarian Cancer Drug Zejula Shows Historical Results in Combination for Hard-to-Treat Cancer
KEY POINTS Zejula plus Keytruda improved the clinical benefits significantly in difficult-to-treat ovarian cancer patients than any one of them ...
Merck’s New Class of Drugs Shows Potential against Resistant Cancers
KEY POINTS ERK inhibitors are the new class of drugs in development for resistant cancers Merck’s ERK inhibitor, MK-8353 in ...
8 Most Promising Vaccines Under Development (2018)
KEY POINTS Here are some of the most promising vaccines on their way in 2018. Vaccines protect against a large ...
Pfizer’s Lorlatinib Gets FDA Priority Review Status to Treat ALK-Positive Lung Cancer
KEY POINTS Lorlatinib is a next-generation ALK/ROS1 tyrosine kinase inhibitor. Last year, lorlatinib had received Breakthrough Therapy designation from the ...
Lupin & Yoshindo’s First Enbrel Biosimilar Targets Regulatory Approval
KEY POINTS YL Biologics announced the successful clinical outcome of YLB113- biosimilar version of Amgen’s blockbuster rheumatoid arthritis drug, Enbrel® ...
US FDA Fast Tracked Takeda’s Zika Virus Vaccine
KEY POINTS Takeda’s inactivated, whole Zika virus vaccine candidate- TAK-426 (PIZV) received ‘fast track’ status The initial ZIK-101 study results ...
CGRP Inhibitors: New Migraine Preventive Treatments Coming Soon to the Market
KEY POINTS New treatment option- anti-CGRP drugs, to prevent a migraine is expected to reach the market in 2018. Allergan’s ...